GlassScriptPhysician profile
Ruben A Tejada
NPI 1053473231
$6,037.20
in general payments reported to CMS, 2019-2025
36 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $649 · 2021: $1,309 · 2022: $997 · 2023: $827 · 2024: $730 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,074.79 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $834.29 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $738.02 | 2019-2025 | Vraylar, Ubrelvy |
| Antares Pharma, INC. | $548.66 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Horizon Therapeutics Plc | $466.39 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $384.38 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Pfizer INC. | $220.72 | 2025 | |
| Dexcom, INC. | $198.16 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $182.51 | 2019-2021 | |
| Esperion Therapeutics, INC. | $159.18 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $154.22 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $138.88 | 2021-2023 | Mounjaro |
| Amgen INC. | $103.28 | 2021-2025 | Repatha, Otezla, Otezla |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Mylan Specialty L.P. | $91.99 | 2023-2024 | Yupelri |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.81 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $68.25 | 2021-2023 | Belsomra, Steglatro |
| Eisai INC. | $57.00 | 2020-2021 | |
| Abbott Laboratories | $46.68 | 2021-2024 | Freestyle Libre |
| Halozyme INC | $39.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $36.50 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.95 | 2023-2025 | |
| Corium, LLC | $33.93 | 2022-2023 | Adlarity |
| Inspire Medical Systems, INC. | $31.08 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $30.11 | 2023 | Sunosi |
| Ibsa Pharma INC. | $27.59 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.73 | 2019 | |
| Exact Sciences Corporation | $19.73 | 2025 | Cologuard Collection Kit |
| Kaleo, INC. | $18.79 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.58 | 2022 | |
| Redhill Biopharma INC. | $15.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.15 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.30 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2021 | |
| Allergan, INC. | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Tejada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.